Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03668353
Other study ID # BF30A101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 5, 2018
Est. completion date September 1, 2020

Study information

Verified date September 2018
Source Shenzhen Salubris Pharmaceuticals Co., Ltd.
Contact Wei Ye
Phone 86-13601158377
Email yewill18@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lower extremity arteriosclerosis obliterans is due to the formation of atherosclerotic plaque in the lower extremities, resulting in the stenosis and occlusion of the artery, leading to chronic ischemia of the limbs. Although bypass surgery and angioplasty ( or interventional therapy ) are effective methods for vascular treatment in patients with PAD to revascularize, a significant proportion of patients with the arterial disease are not eligible for direct arterial surgery. Meanwhile, there are many patients who suffer from diffuse arterial disease or severe peripheral disease not suitable for interventional therapy. Stimulation of arteriogenesis( blood bypassing the occluded arteries through a large number of collateral vessels ) and angiogenesis ( generating new small blood vessels ) have become the focus of research.

Our recombinant SeV-hFGF2/dF injection (R&D code BF30 ) uses the human basic fibroblast growth factor ( FGF2 ) gene to express the target protein FGF2 locally by intramuscular injection. The preparation can efficiently express FGF2 in infected cells and secrete it to the periphery and be fixed in the intercellular substance. Since FGF2 is in the upstream regulatory pathway of VEGF, HGF and other factors, it can regulate the coordinated expression of these cytokines related to the growth and function of new blood vessels, and finally, produce mature blood vessels.

To evaluate the safety ( tolerance), pharmacokinetics (PK), biological activity, and immunogenicity of BF30 in patients with lower extremity arterial occlusive disease, and to explore clinical benefits.

MAIN OBJECTIVE: To evaluate the safety ( tolerability ) of single-dose BF30 in patients with lower extremity arterial occlusive disease, and to provide evidence for the dose of subsequent clinical trials.

Secondary objective: To explore the pharmacokinetics (PK), biological activity, the immunogenicity of BF30, and to initially explore clinical benefits.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date September 1, 2020
Est. primary completion date March 5, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Male or female, aged 18-80 years old, weighing > 50kg, with an expected survival of more than 1 year;

- diagnosed as Lower extremity arterial occlusive disease (ASO , DAO , TAO) , and Rutherford grade 2 to 5 (moderate intermittent claudication - mild tissue defect), if both of the subject's limbs have lower extremity arterial ischemic disease, the limb that could not be revascularized or more severe one to study by the investigator;

- Patients are not eligible for revascularization (eg, interventional endovascular treatment or surgery); or patients who have failed previous revascularization treatment;

- For patients who are taking cilostazol, prostaglandins or sarpogrelate for the treatment of lower limb ischemia, a stable dose should be used for at least 1 month before the test drug is injected ;

- Before enrollment, confirmed by DSA or CTA as the superficial femoral artery ( ie, the femoral artery below the branch of the deep femoral artery), one or more stenosis of the radial artery and its lower artery = 75% or occlusion;

- The intended to treat lower extremity ABI = 0.9 ;

- Volunteer to participate in the trial and sign the informed consent form.

Exclusion Criteria:

- Patients with malignant tumors or clinically significant history of a hematological disease, or clinically significant results of tumor screening tests;

- Patients with a history of alcohol or drug abuse in the last 12 months;

- The affected limb may need an amputation in 4 weeks;

- Acute lower extremity arterial ischemic disease or acute progressive disease of lower extremity arterial ischemic disease;

- The index limb has serious infections ( such as cellulitis, osteomyelitis, etc.), distal fascia or bone exposure;

- Cardiac function is classified as grade III or IV heart failure according to the New York Heart Association (NYHA) ;

- Patients with cerebral infarction, cerebral hemorrhage, myocardial infarction, and unstable angina in the past 3 months;

- Type I diabetes patients;

- Poorly controlled hypertension up to three antihypertensive drugs combined, defined as those at screening or baseline testing: systolic blood pressure > 160 mmHg or diastolic blood pressure > 110 mmHg ;

- Patients with grade 3 and above proliferative retinopathy history;

- Currently receiving immunosuppressive agents or radiotherapy and chemotherapy;

- Antiviral drugs, drugs for inhibiting u-PA activity, such as diuretics, amiloride, and suramin, were used within 2 weeks before administration ;

- Subjects included: HIV, hepatitis B, hepatitis C, routine hematology laboratory tests found that patients with significant clinical significance ( hepatitis B virus carriers can be selected); or blood routine, blood biochemistry, liver function, etc. Any of the following abnormalities (if the investigator judges that the abnormality may be caused by the inspection operation, still exists after one retest):

- TBIL exceeds 1.5 times the normal upper limit or ALT/AST exceeds 2.5 times the upper limit of normal

- Serum creatinine or urea nitrogen > 1.2 times the upper limit of normal

- Hemoglobin (Hb) < 8.5 g/dL

- White blood cell count < 3 × 10 9 /L

- Platelet count < 75 × 10 9 / L

- Fasting blood glucose > 13.9 mmol/L

- HbA1c > 10%

- Donate blood in last 1 month or participate in other intervention clinical trials;

- Childbearing age (male/female) do not agree to adopt recognized effective contraceptives during study treatment and at least 6 months after completion of the study , and / or women of childbearing age who are unwilling or unable to undergo pregnancy tests; pregnancy, Lactating women ( where pregnancy is defined as a positive blood test ) ;

- Other clinically uncontrollable diseases, including but not limited to: a severe liver disease with decompensated cirrhosis, jaundice, ascites or hemorrhagic varices;

- Patients undergoing dialysis;

- a history of allergic to lidocaine, or patients whose may be allergic to the study drug or its components determined by the investigator;

- Other factors that may affect drug safety, effectiveness, and drug metabolism evaluation determined by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant SeV-hFGF2/dF Injection
intramuscular injection of investigator drugs

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment- Emergent Adverse Events [Safety and Tolerability] AE incidence, inject site reactions 6 months
Secondary Maximum Plasma Concentration [Cmax] serum concentration of total RNA 6 months after drug administration
Secondary Area Under the Curve [AUC] serum concentration of total RNA 6 months after drug administration
Secondary antibody of the SeV Immunogenecity 6 months after drug administration
Secondary walking distance walking function 6 months after drug administration
Secondary pain scale using VAS scale 6 months after drug administration
Secondary Ruthorford staging improvements after study drug use. 6 months after drug administration
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT04110964 - Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT Phase 1
Not yet recruiting NCT03994666 - Cell Therapy in Critical Limb Ischemia Phase 2
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Not yet recruiting NCT02498080 - Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Recruiting NCT02239419 - Evaluation of Carbothera in the Treatment of Foot Ulcers N/A
Recruiting NCT01938872 - Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia N/A
Active, not recruiting NCT01211925 - Distal Venous Arterialisation of Ischemic Limb Phase 2/Phase 3
Completed NCT02454231 - Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA) Phase 2/Phase 3
Completed NCT01758874 - Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia Phase 2
Completed NCT02475200 - Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
Recruiting NCT04583436 - Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia N/A
Completed NCT04071782 - Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore N/A
Completed NCT03669458 - Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy. N/A
Not yet recruiting NCT06007469 - Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
Recruiting NCT04110327 - An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Completed NCT02260622 - Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia Phase 2
Recruiting NCT02054416 - External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality N/A
Not yet recruiting NCT01446055 - Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia Phase 1/Phase 2